|Bid||1.3100 x N/A|
|Ask||1.3400 x N/A|
|Day's Range||1.3100 - 1.3300|
|52 Week Range||0.3900 - 1.5000|
|Beta (5Y Monthly)||1.14|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov. 22, 2021 - Nov. 29, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), is pleased to announce that it has received conditional acceptance from the TSX Venture Exchange to make a Normal Course Issuer Bid ("NCIB") to purchase for cancellation, during the 12-month period starting October 25, 2021, up to 3,844,081 of the Common Shares, representing 5% of the Common Shares outstanding as of October 25, 2021. The program will end on October 24, 2022, the maximum amount of Common Shares is pur
Nanalysis Scientific Corp. ("the Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable MRI and NMR machines for healthcare and industrial applications, announces that it has retained Firm IR Group as an investor relations advisor. Firm IR Group will assist the Company with its investor relations program consisting of corporate communications, investor and shareholder outreach.
CALGARY, AB / ACCESSWIRE / September 30, 2021 /Nanalysis Scientific Corp. ("Nanalysis") (TSXV:NSCI)(OTCQX:NSCIF)(FRA:1N1), is pleased to share its fall investor conference schedule.